Open Access

Association study between clinical response to rizatriptan and some candidate genes

  • Carlo Asuni1Email author,
  • Allesandra Cherchi1,
  • Donatella Congiu1,
  • Maria P. Piccardi1,
  • Maria Del Zompo1 and
  • Maria E. Stochino1
The Journal of Headache and Pain20078:388

https://doi.org/10.1007/s10194-007-0388-5

Received: 27 November 2006

Accepted: 19 February 2007

Published: 11 June 2007

Abstract

The aim of this study was to test genetic differences in the clinical response to rizatriptan in patients affected by migraine without aura. These genetic differences could be explained by various genes, the HTR1B, encoding the 5-HT1 receptor subtype, MAOA gene that encodes the monoamino-oxidase, the main metabolic enzyme of this triptan, SLC6A4 (gene encoding the serotonin transporter) and DRD2 (gene encoding the D2 receptor), both involved in the pathogenesis of migraine. Fifty unrelated patients affected by migraine without aura (IHS) were included. Patients were divided into two groups (responders and non-responders) according to clinical response. Thirty-one out of fifty patients responded to rizatriptan. A significant difference among the two groups was observed in both allele (p=0.02) and genotype distribution (p=0.03) of DRD2/NcoI. The significant association with the DRD2/NcoI polymorphism in responders suggested that the DRD2/NcoI C allele may be considered a susceptibility factor heralding a good response to rizatriptan.

Keywords

Migraine Triptans Pharmacogenetics Dopamine DRD2